127 related articles for article (PubMed ID: 15791453)
1. Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer.
Murakami J; Asaumi J; Kawai N; Tsujigiwa H; Yanagi Y; Nagatsuka H; Inoue T; Kokeguchi S; Kawasaki S; Kuroda M; Tanaka N; Matsubara N; Kishi K
Cancer Chemother Pharmacol; 2005 Jul; 56(1):22-8. PubMed ID: 15791453
[TBL] [Abstract][Full Text] [Related]
2. Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
Okegawa T; Nutahara K; Pong RC; Higashihara E; Hsieh JT
J Urol; 2005 Aug; 174(2):747-52. PubMed ID: 16006969
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells.
Hou M; Wang X; Popov N; Zhang A; Zhao X; Zhou R; Zetterberg A; Björkholm M; Henriksson M; Gruber A; Xu D
Exp Cell Res; 2002 Mar; 274(1):25-34. PubMed ID: 11855854
[TBL] [Abstract][Full Text] [Related]
5. Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors.
Zhu K; Qu D; Sakamoto T; Fukasawa I; Hayashi M; Inaba N
Arch Gynecol Obstet; 2008 Jan; 277(1):15-9. PubMed ID: 17680259
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines.
Tsurutani J; Soda H; Oka M; Suenaga M; Doi S; Nakamura Y; Nakatomi K; Shiozawa K; Amada YY; Kamihira S; Kohno S
Int J Cancer; 2003 Mar; 104(2):238-42. PubMed ID: 12569581
[TBL] [Abstract][Full Text] [Related]
7. Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor.
Wu P; Meng L; Wang H; Zhou J; Xu G; Wang S; Xi L; Chen G; Wang B; Zhu T; Lu Y; Ma D
Biochem Biophys Res Commun; 2005 Sep; 335(1):36-44. PubMed ID: 16051188
[TBL] [Abstract][Full Text] [Related]
8. Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells.
Chang JT; Yang HT; Wang TC; Cheng AJ
Mol Carcinog; 2005 Nov; 44(3):183-92. PubMed ID: 16010690
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells.
Khaw AK; Silasudjana M; Banerjee B; Suzuki M; Baskar R; Hande MP
Mutat Res; 2007 Dec; 625(1-2):134-44. PubMed ID: 17669439
[TBL] [Abstract][Full Text] [Related]
10. Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis.
Cheng YW; Wu TC; Chen CY; Chou MC; Ko JL; Lee H
Clin Cancer Res; 2008 Nov; 14(22):7173-9. PubMed ID: 19010833
[TBL] [Abstract][Full Text] [Related]
11. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.
Nakajima H; Kim YB; Terano H; Yoshida M; Horinouchi S
Exp Cell Res; 1998 May; 241(1):126-33. PubMed ID: 9633520
[TBL] [Abstract][Full Text] [Related]
12. Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells.
Jagadeesh S; Kyo S; Banerjee PP
Cancer Res; 2006 Feb; 66(4):2107-15. PubMed ID: 16489011
[TBL] [Abstract][Full Text] [Related]
13. Expression of human telomerase reverse transcriptase splice variants is well correlated with low telomerase activity in osteosarcoma cell lines.
Fujiwara-Akita H; Maesawa C; Honda T; Kobayashi S; Masuda T
Int J Oncol; 2005 Apr; 26(4):1009-16. PubMed ID: 15753996
[TBL] [Abstract][Full Text] [Related]
14. [Relationship among telomerase activity, expression of human telomerase reverse transcriptase (hTERT), and expression of c-myc in acute leukemia].
Cheng X; Chen ZX; Wang W; Fu JX; Cen JN; Yao L
Ai Zheng; 2003 Nov; 22(11):1175-9. PubMed ID: 14613647
[TBL] [Abstract][Full Text] [Related]
15. Expression of the human telomerase reverse transcriptase is not related to telomerase activity in normal and malignant renal tissue.
Rohde V; Sattler HP; Bund T; Bonkhoff H; Fixemer T; Bachmann C; Lensch R; Unteregger G; Stoeckle M; Wullich B
Clin Cancer Res; 2000 Dec; 6(12):4803-9. PubMed ID: 11156238
[TBL] [Abstract][Full Text] [Related]
16. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
Liu C; Fang X; Ge Z; Jalink M; Kyo S; Björkholm M; Gruber A; Sjöberg J; Xu D
Cancer Res; 2007 Mar; 67(6):2626-31. PubMed ID: 17363582
[TBL] [Abstract][Full Text] [Related]
17. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation.
Greenberg RA; O'Hagan RC; Deng H; Xiao Q; Hann SR; Adams RR; Lichtsteiner S; Chin L; Morin GB; DePinho RA
Oncogene; 1999 Feb; 18(5):1219-26. PubMed ID: 10022128
[TBL] [Abstract][Full Text] [Related]
18. Antisense human telomerase reverse transcriptase could partially reverse malignant phenotypes of gastric carcinoma cell line in vitro.
Yang SM; Fang DC; Yang JL; Chen L; Luo YH; Liang GP
Eur J Cancer Prev; 2008 Jun; 17(3):209-17. PubMed ID: 18414191
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues.
Fan Y; Liu Z; Fang X; Ge Z; Ge N; Jia Y; Sun P; Lou F; Björkholm M; Gruber A; Ekman P; Xu D
Clin Cancer Res; 2005 Jun; 11(12):4331-7. PubMed ID: 15958614
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific activation of hTERT-derived promoters by tumor suppressive E1A-mutants involves recruitment of p300/CBP/HAT and suppression of HDAC-1 and defines a combined tumor targeting and suppression system.
Kirch HC; Ruschen S; Brockmann D; Esche H; Horikawa I; Barrett JC; Opalka B; Hengge UR
Oncogene; 2002 Nov; 21(52):7991-8000. PubMed ID: 12439749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
